Silexion Therapeutics SLXN
NASDAQ SLXN
$0.28 0.00 (-0.43%)
As of: Oct 2, 2026 · 1:04 PM EDT

Silexion Therapeutics (SLXN) Return on Equity [ROE] (2024 - 2026)

Updated

Silexion Therapeutics' Return on Equity [ROE] was -8333.13% in Q2 2026, down 7014.21 percentage points from -1318.92% a year earlier and down 7440.94 percentage points from the prior quarter.

Analysis

Silexion Therapeutics (SLXN) Return on Equity [ROE] (2024 - 2026) Analysis & Trends

From Q2 2024 onward, Silexion Therapeutics has reported Return on Equity [ROE] for 6 quarters.

  • Per Business Quant data, SLXN's Return on Equity [ROE] in the three quarters before Q2 2026 was -892.19% (Q1 2026), -248.68% (Q4 2025) and -260.59% (Q3 2025).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) ROE (Qtr)
1 Johnson & Johnson 638.12 Bn 556.64 Bn 17.26 Bn 25.32%
2 AbbVie 462.60 Bn 435.75 Bn 12.70 Bn -
3 Merck 358.70 Bn 313.13 Bn 12.21 Bn 7.21%
4 Novartis Ag 272.16 Bn 228.03 Bn 11.24 Bn 84.40%
5 Astrazeneca 250.36 Bn 223.92 Bn 12.86 Bn 21.39%
6 Amgen 227.87 Bn 183.27 Bn 7.24 Bn 83.75%
7 Gilead Sciences 184.97 Bn 159.08 Bn 6.22 Bn -18.38%
8 Pfizer 162.61 Bn 109.56 Bn 10.94 Bn 4.97%
9 Vertex Pharmaceuticals 132.45 Bn 104.46 Bn 2.84 Bn 22.24%
10 Silexion Therapeutics 192,458.84 -19.68 Mn - -8,333.13%
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -8,333.13%
Mar 31, 2026 -892.19%
Dec 31, 2025 -248.68%
Sep 30, 2025 -260.59%
Jun 30, 2025 -1,318.92%
Jun 30, 2024 -610.78%
API Access

Silexion Therapeutics Return on Equity [ROE] API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=return-on-equity-%5Broe%5D&ticker=SLXN&period=max&api_key=YOUR_API_KEY